How the immune system is shaped in the womb and in early infancy may matter far more than previously appreciated — and the tools scientists use to detect chemical threats to that process are finally catching up. For decades, a troubling gap has existed between what toxicology laboratories can measure and what actually happens to the developing human immune system when it encounters environmental chemicals. A comprehensive review in Archives of Toxicology maps both the biological landscape and the methodological frontier that is beginning to close that gap.
The review centers on developmental immunotoxicology (DIT), the field studying how xenobiotic exposures during fetal and early postnatal windows can permanently alter immune competence, tolerance thresholds, and long-term disease susceptibility. The authors trace immune ontogeny from embryogenesis through postnatal maturation, identifying discrete periods of heightened vulnerability where disruptions appear most consequential. Central to the analysis are New Approach Methodologies (NAMs) — a class of human-relevant in vitro and computational tools designed to model immune development without relying on animal models that often fail to recapitulate human immune ontogeny. Multi-omics platforms and physiological mapping are highlighted as particularly valuable for connecting mechanistic pathways to real-world epidemiological signals and identifying candidate biomarkers.
The implications of this methodological pivot deserve careful attention. Traditional animal-based DIT testing has long been criticized for poor translational fidelity; mouse and rat immune development diverges substantially from humans in both timing and mechanistic detail. NAMs represent a genuine opportunity to improve predictive accuracy, but the review is candid about a persistent challenge: ensuring that in vitro models adequately cover all critical developmental windows and the full breadth of immune mechanisms that may be disrupted. This is not a solved problem. The scarcity of well-characterized human reference data — against which NAM outputs must be validated — remains a structural constraint. As a regulatory review rather than an original clinical study, this work is best understood as a framework document rather than a source of specific causal findings, but it signals meaningful momentum toward testing standards that more faithfully reflect human developmental biology.